466 related articles for article (PubMed ID: 27468203)
1. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
2. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract][Full Text] [Related]
3. Metformin does not improve survival in patients with hepatocellular carcinoma.
Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
[TBL] [Abstract][Full Text] [Related]
4. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
5. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.
Chen HH; Lin MC; Muo CH; Yeh SY; Sung FC; Kao CH
Medicine (Baltimore); 2015 Jun; 94(24):e1013. PubMed ID: 26091447
[TBL] [Abstract][Full Text] [Related]
7. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.
Zhang ZJ; Zheng ZJ; Shi R; Su Q; Jiang Q; Kip KE
J Clin Endocrinol Metab; 2012 Jul; 97(7):2347-53. PubMed ID: 22523334
[TBL] [Abstract][Full Text] [Related]
8. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
10. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
11. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Wang K; Zhang K; Zhang X; Chen D; Jiang S
Mini Rev Med Chem; 2023; 23(11):1154-1166. PubMed ID: 35747976
[TBL] [Abstract][Full Text] [Related]
12. Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases.
Wang CP; Kuhn J; Shah DP; Schmidt S; Lam YF; MacCarthy D; Tenner L; Ramirez AG
Cancer Med; 2019 Jun; 8(6):3206-3215. PubMed ID: 30993905
[TBL] [Abstract][Full Text] [Related]
13. Metformin therapy and its anti-neoplastic role in systemic malignancies besides hepatocellular carcinomas.
Kapoor S
Scand J Gastroenterol; 2013 May; 48(5):636-7. PubMed ID: 23477305
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
16. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
17. Editorial: hepatocellular carcinoma in type 2 diabetes: more than meets the eye.
Baffy G
Am J Gastroenterol; 2012 Jan; 107(1):53-5. PubMed ID: 22218030
[TBL] [Abstract][Full Text] [Related]
18. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Chen HP; Shieh JJ; Chang CC; Chen TT; Lin JT; Wu MS; Lin JH; Wu CY
Gut; 2013 Apr; 62(4):606-15. PubMed ID: 22773548
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Noureddin M; Rinella ME
Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
